Meletios-Athanasios Dimopoulos
Overview
Explore the profile of Meletios-Athanasios Dimopoulos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
178
Citations
2324
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Soureas K, Malandrakis P, Papadimitriou M, Minopoulos C, Ntanasis-Stathopoulos I, Liacos C, et al.
Blood Cancer J
. 2025 Mar;
15(1):41.
PMID: 40089465
The persistence of high relapse rates and therapy resistance continues to challenge the effective management of multiple myeloma (MM). The identification of novel MM-specific molecular markers could ameliorate risk-stratification tools...
2.
Flora Z, Zagouri F, Dimopoulos M, Andrikopoulou A
Crit Rev Oncol Hematol
. 2025 Mar;
:104696.
PMID: 40068804
Approximately 1 in 10 women diagnosed with breast cancer before the age of 35 carry germline BRCA pathogenic/likely pathogenic variants. Poly (ADP-ribose) polymerase (PARP) inhibitors have been recently approved in...
3.
Paschou S, Andrikopoulou A, Mili N, Svarna A, Kaparelou M, Stefanaki K, et al.
Nutrients
. 2025 Feb;
17(3).
PMID: 39940415
Background/objectives: Survival rates for ovarian cancer remain distressingly low. Despite established prognostic factors, the need to identify modifiable parameters to influence survival outcomes is imperative. Overweight and obesity, both prevalent...
4.
Katodritou E, Kastritis E, Dalampira D, Fotiou D, Theodorakakou F, Delimpasi S, et al.
Clin Lymphoma Myeloma Leuk
. 2025 Feb;
PMID: 39919999
Background: Despite treatment improvements a considerable proportion of newly diagnosed multiple myeloma (MM) patients experience early progressive disease (EPD) defined as progression or relapse in < 18 months following initial...
5.
Theodorakakou F, Fotiou D, Spiliopoulou V, Migkou M, Malandrakis P, Ntanasis-Stathopoulos I, et al.
Amyloid
. 2025 Feb;
:1-3.
PMID: 39905642
No abstract available.
6.
Andrikopoulou A, Zagouri F, Goula K, Haidopoulos D, Thomakos N, Svarna A, et al.
BMC Cancer
. 2024 Dec;
24(1):1503.
PMID: 39639215
Human epidermal growth factor receptor 2 (HER2) overexpression emerges as an attractive therapeutic target in gynecological malignancies. Recently, Trastuzumab-Deruxtecan (T-DXd) has shown substantial efficacy in HER2 overexpressing carcinomas, most prominently...
7.
Yong K, Martin T, Dimopoulos M, Mikhael J, Capra M, Facon T, et al.
Lancet Haematol
. 2024 Jul;
11(10):e741-e750.
PMID: 39067465
Background: Isatuximab is an anti-CD38 monoclonal antibody approved for the treatment of relapsed or refractory multiple myeloma. Previous analyses of the IKEMA trial showed prolonged progression-free survival in patients with...
8.
Tatouli I, Dedes N, Bozikas A, Melliou S, Pavlou M, Kontogiannis S, et al.
Microorganisms
. 2024 Jul;
12(7).
PMID: 39065149
Immunocompromised patients with hematologic diseases may experience life-threatening infections with rather uncommon manifestations. Laryngitis has been described as a potential infection in such vulnerable patients and may result in major...
9.
Andrikopoulou A, Goga K, Stefanaki K, Paschou S, Athanasopoulos S, Zagouri F, et al.
Oncol Lett
. 2024 Jul;
28(3):417.
PMID: 39006947
Cushing's syndrome (CS), as a result of ectopic adrenocorticotropic hormone (ACTH) production, constitutes a common paraneoplastic manifestation of various malignancies, with the most common being small cell lung carcinoma. In...
10.
Kapoor P, Nathwani N, Jelinek T, Pour L, Perrot A, Dimopoulos M, et al.
Eur J Haematol
. 2024 Jul;
113(5):593-605.
PMID: 38993150
Objectives: Cluster of differentiation 38 (CD38) is a key target on multiple myeloma (MM) cells. This multi-centre, Phase 1, single-agent study (NCT04000282) investigated SAR442085, a novel fragment crystallisable (Fc)-modified anti-CD38...